Findings from the first two years of a five-year,real-world study, which was published in the Journal of Clinical Oncology (JCO)reveal that Comprehensive Genomic Profiling (CGP), when done early in a cancerpatient’s diagnosis, leads to better personalized treatment and patientoutcomes.
This new research by Providence, Illumina, and Microsoftshowed that using CGP testing finds more useful genetic changes than an older50-gene test. Patients tested with CGP were more likely to get targetedtreatments and lived longer when tested at diagnosis. However, not all patientsget CGP testing, so there are still some gaps in who benefits from this approach.
